558 related articles for article (PubMed ID: 33740349)
41. Opioids and neuropathic pain.
Smith HS
Pain Physician; 2012 Jul; 15(3 Suppl):ES93-110. PubMed ID: 22786465
[TBL] [Abstract][Full Text] [Related]
42. A patent review of transient receptor potential vanilloid type 1 modulators (2014-present).
Gao M; Wang Y; Liu L; Qiao Z; Yan L
Expert Opin Ther Pat; 2021 Feb; 31(2):169-187. PubMed ID: 33377418
[No Abstract] [Full Text] [Related]
43. Hot receptors in the brain.
Steenland HW; Ko SW; Wu LJ; Zhuo M
Mol Pain; 2006 Nov; 2():34. PubMed ID: 17092351
[TBL] [Abstract][Full Text] [Related]
44. Peripherally acting opioid analgesics and peripherally-induced analgesia.
Martínez V; Abalo R
Behav Pharmacol; 2020 Apr; 31(2&3):136-158. PubMed ID: 32168025
[TBL] [Abstract][Full Text] [Related]
45. Delta and kappa opioid receptors as suitable drug targets for pain.
Vanderah TW
Clin J Pain; 2010 Jan; 26 Suppl 10():S10-5. PubMed ID: 20026960
[TBL] [Abstract][Full Text] [Related]
46. Discovery of dual-acting opioid ligand and TRPV1 antagonists as novel therapeutic agents for pain.
Lee H; Ahn S; Ann J; Ha H; Yoo YD; Kim YH; Hwang JY; Hur KH; Jang CG; Pearce LV; Esch TE; Lewin NE; Blumberg PM; Lee J
Eur J Med Chem; 2019 Nov; 182():111634. PubMed ID: 31472474
[TBL] [Abstract][Full Text] [Related]
47. Additive antinociceptive effects of the selective Nav1.8 blocker A-803467 and selective TRPV1 antagonists in rat inflammatory and neuropathic pain models.
Joshi SK; Honore P; Hernandez G; Schmidt R; Gomtsyan A; Scanio M; Kort M; Jarvis MF
J Pain; 2009 Mar; 10(3):306-15. PubMed ID: 19070548
[TBL] [Abstract][Full Text] [Related]
48. The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice.
Paton KF; Kumar N; Crowley RS; Harper JL; Prisinzano TE; Kivell BM
Eur J Pain; 2017 Jul; 21(6):1039-1050. PubMed ID: 28158929
[TBL] [Abstract][Full Text] [Related]
49. Antiallodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute postsurgical pain: evidence for analgesic synergy with opioids and baclofen.
Mueller A; Starobova H; Morgan M; Dekan Z; Cheneval O; Schroeder CI; Alewood PF; Deuis JR; Vetter I
Pain; 2019 Aug; 160(8):1766-1780. PubMed ID: 31335646
[TBL] [Abstract][Full Text] [Related]
50. Analgesic effects of the novel semicarbazide-sensitive amine oxidase inhibitor SZV 1287 in mouse pain models with neuropathic mechanisms: Involvement of transient receptor potential vanilloid 1 and ankyrin 1 receptors.
Horváth Á; Tékus V; Bencze N; Szentes N; Scheich B; Bölcskei K; Szőke É; Mócsai A; Tóth-Sarudy É; Mátyus P; Pintér E; Helyes Z
Pharmacol Res; 2018 May; 131():231-243. PubMed ID: 29438782
[TBL] [Abstract][Full Text] [Related]
51. Palvanil, a non-pungent capsaicin analogue, inhibits inflammatory and neuropathic pain with little effects on bronchopulmonary function and body temperature.
Luongo L; Costa B; D'Agostino B; Guida F; Comelli F; Gatta L; Matteis M; Sullo N; De Petrocellis L; de Novellis V; Maione S; Di Marzo V
Pharmacol Res; 2012 Sep; 66(3):243-50. PubMed ID: 22634607
[TBL] [Abstract][Full Text] [Related]
52. Tetrahydropyridine-4-carboxamides as novel, potent transient receptor potential vanilloid 1 (TRPV1) antagonists.
Brown BS; Keddy R; Zheng GZ; Schmidt RG; Koenig JR; McDonald HA; Bianchi BR; Honore P; Jarvis MF; Surowy CS; Polakowski JS; Marsh KC; Faltynek CR; Lee CH
Bioorg Med Chem; 2008 Sep; 16(18):8516-25. PubMed ID: 18722778
[TBL] [Abstract][Full Text] [Related]
53. Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
Chen SR; Pan HL
J Neurophysiol; 2006 May; 95(5):3086-96. PubMed ID: 16467418
[TBL] [Abstract][Full Text] [Related]
54. Progress of clinical practice on the management of burn-associated pain: Lessons from animal models.
McIntyre MK; Clifford JL; Maani CV; Burmeister DM
Burns; 2016 Sep; 42(6):1161-72. PubMed ID: 26906668
[TBL] [Abstract][Full Text] [Related]
55. Analgesic effects of cuminic alcohol (4-isopropylbenzyl alcohol), a monocyclic terpenoid, in animal models of nociceptive and neuropathic pain: Role of opioid receptors, L-arginine/NO/cGMP pathway, and inflammatory cytokines.
Sheikholeslami MA; Ghafghazi S; Parvardeh S; Koohsari S; Aghajani SH; Pouriran R; Vaezi LA
Eur J Pharmacol; 2021 Jun; 900():174075. PubMed ID: 33811835
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of multimodal analgesic treatment of severe traumatic acute pain in mice pretreated with chronic high dose of buprenorphine inducing mechanical allodynia.
Coutens B; Derreumaux C; Labaste F; Minville V; Guiard BP; Moulédous L; Bounes V; Roussin A; Frances B
Eur J Pharmacol; 2020 May; 875():172884. PubMed ID: 31870829
[TBL] [Abstract][Full Text] [Related]
57. Targeting TRPV1 for pain relief: limits, losers and laurels.
Szallasi A; Sheta M
Expert Opin Investig Drugs; 2012 Sep; 21(9):1351-69. PubMed ID: 22780443
[TBL] [Abstract][Full Text] [Related]
58. Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy.
Kwiatkowski K; Pawlik K; Ciapała K; Piotrowska A; Makuch W; Mika J
Front Immunol; 2020; 11():615327. PubMed ID: 33408720
[TBL] [Abstract][Full Text] [Related]
59. μ-Opioid receptors in primary sensory neurons are essential for opioid analgesic effect on acute and inflammatory pain and opioid-induced hyperalgesia.
Sun J; Chen SR; Chen H; Pan HL
J Physiol; 2019 Mar; 597(6):1661-1675. PubMed ID: 30578671
[TBL] [Abstract][Full Text] [Related]
60. Replacement of current opioid drugs focusing on MOR-related strategies.
Busserolles J; Lolignier S; Kerckhove N; Bertin C; Authier N; Eschalier A
Pharmacol Ther; 2020 Jun; 210():107519. PubMed ID: 32165137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
